Krystal Biotech, Inc.
KRYS
Rangering i aksjer
#2153
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Aksjekurs
$320.50
Markedsverdi
$9.49B
Endring (1 dag)
1.24%
Endring (1 år)
68.48%
Land
US
Handel Krystal Biotech, Inc. (KRYS)
Kategori
Healthcare
EPS for Krystal Biotech, Inc. (KRYS)
EPS per June 2026 TTM: $8.27
Ifølge de siste økonomiske rapportene og aksjekursen til Krystal Biotech, Inc. er selskapets nåværende EPS (TTM) $8.27. Ved slutten av 2023 hadde selskapet en EPS på $0.40, en økning sammenlignet med EPS-en i 2022 som var $-5.49.
EPS-historikk for Krystal Biotech, Inc. fra 2016 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $8.27 | 165.06% |
| 2024 | $3.12 | 680.00% |
| 2023 | $0.40 | -107.29% |
| 2022 | $-5.49 | 75.40% |
| 2021 | $-3.13 | 83.04% |
| 2020 | $-1.71 | 42.50% |
| 2019 | $-1.20 | 23.71% |
| 2018 | $-0.97 | -34.46% |
| 2017 | $-1.48 | 448.15% |
| 2016 | $-0.27 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | 109.43% |
US
|
|
| $-7.98 | -196.49% |
US
|
|
| $-5.29 | -163.97% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 235.43% |
NL
|
